GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Formycon AG (XTER:FYB) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 17, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Formycon AG's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Formycon AG's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Formycon AG's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Formycon AG's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Formycon AG's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Formycon AG  (XTER:FYB) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Formycon AG Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Formycon AG's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
XTER:HPHA STU:T9G XTER:MDG1 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269
Traded in Other Exchanges
0W4N:UK
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Website
https://www.formycon.com
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.
Executives
Dr. Nicola Mikulcik Board of Directors
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG Headlines

No Headlines